Herpes Zoster Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The market size of Herpes Zoster is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immoma Biotherapeutics Inc., Icon Plc, Pascoe Pharmazeutische Praeparate GmbH, GlaxoSmithKline, Astellas Pharma Inc., Yung Shin Pharm Ind. Co. Ltd., Jiangsu Rec-Biotechnology Co., Ltd., Maruho Co. Ltd., Epiphany Biosciences, EMS, Nobelpharma, Bristol-Myers Squibb.

[Nevada, United States] - DelveInsight's "Herpes Zoster Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Herpes Zoster, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Herpes Zoster Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/herpes-zoster-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Herpes Zoster Market Report:
The Herpes Zoster market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In August, 2024: ModernaTX, Inc. announced that the purpose of their clinical trial is to evaluate the safety and immunogenicity of mRNA-1468.
In August, 2024: Pfizer announced that the purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants who are between 50 and 69 years of age.
In August, 2024: Dynavax Technologies Corporation announced a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 440 healthy adults.
In April, 2024: GlaxoSmithKline announced that the purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of age (YOA) or older from India.
As per analysis, nearly all adults in the US, about 98%, have had chickenpox, making them susceptible to shingles. As people age, the risk of shingles increases, highlighting the importance of vaccination, especially for those aged 50 and older. Additionally, individuals with weakened immune systems should also receive the shingles vaccine. Although rare in children, shingles can still occur, albeit uncommonly.
Based on our secondary analysis, in Japan the herpes zoster prevalence among individuals in the general population aged 50 years and above is approximately 10 per 1000 person-years (PY), with a higher prevalence observed among those aged 60 years and above. Moreover, the incidence escalates to more than 12 per 1000 PY in individuals aged 80 years and older.
Key Herpes Zoster Companies are as follows: Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immoma Biotherapeutics Inc., Icon Plc, Pascoe Pharmazeutische Praeparate GmbH, GlaxoSmithKline, Astellas Pharma Inc., Yung Shin Pharm Ind. Co. Ltd., Jiangsu Rec-Biotechnology Co., Ltd., Maruho Co. Ltd., Epiphany Biosciences, EMS, Nobelpharma, Bristol-Myers Squibb.
Key Herpes Zoster Therapies are as follow: Shingrix, CRV-101, Peginterferon α1b, ASP2151, valaciclovir, Famciclovir, Aciclovir, valacyclovir, FV-100, famciclovir, KD7040 Topical Gel
Launching multiple stage Herpes Zoster pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Herpes Zoster market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Herpes Zoster Overview:
Herpes zoster (HZ), also called as Shingles, is a neurocutaneous disease that is generally caused by the reactivation ofvaricella zoster virus (VZV) from a latent infection of dorsal sensory or cranial nerve ganglia following primary infection withVZV before in life. VZV is explicitly a human virus that belongs to the α-herpes virus family. It is present worldwide and ishighly contagious. More than 90% of adults in the United States acquired the disease in childhood, while the majority ofchildren and young adults have been vaccinated with the live virus vaccine.

Herpes Zoster Drugs Uptake and Pipeline Development Activities:
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into Herpes Zoster Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

For more information about Herpes Zoster companies working in the treatment market, visit Herpes Zoster Clinical Trials

Herpes Zoster Therapies and Key Companies:
Shingrix : GlaxoSmithKline (GSK)
CRV-101: Curevo Inc.
Peginterferon α1b: Shanghai Institute Of Biological Products
ASP2151, valaciclovir: Maruho Co., Ltd.
Famciclovir, Aciclovir: EMS
valacyclovir, FV-100: Bristol-Myers Squibb
famciclovir: Novartis
KD7040 Topical Gel: Kalypsys, Inc.

Herpes Zoster Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Herpes Zoster.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Herpes Zoster Epidemiology Segmentation:
The Herpes Zoster market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Herpes Zoster Total Prevalence
Herpes Zoster Prevalent Cases by severity
Herpes Zoster Gender-specific Prevalence
Herpes Zoster Diagnosed Cases of Episodic and Chronic

Herpes Zoster Market Drivers:
Introduction of Effective Vaccines
Growing Awareness and Immunization Campaigns
Increased Incidence Due to Immunocompromised Conditions
Favorable Reimbursement Policies

Herpes Zoster Market Barriers:
Vaccine Supply and Distribution Challenges
Limited Awareness in Developing Regions
Adverse Events and Safety Concerns
Economic Constraints in Low-Income Populations

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Herpes Zoster Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Herpes Zoster Companies: Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immoma Biotherapeutics Inc., Icon Plc, Pascoe Pharmazeutische Praeparate GmbH, GlaxoSmithKline, Astellas Pharma Inc., Yung Shin Pharm Ind. Co. Ltd., Jiangsu Rec-Biotechnology Co., Ltd., Maruho Co. Ltd., Epiphany Biosciences, EMS, Nobelpharma, Bristol-Myers Squibb.
Key Herpes Zoster Therapies: Shingrix, CRV-101, Peginterferon α1b, ASP2151, valaciclovir, Famciclovir, Aciclovir, valacyclovir, FV-100, famciclovir, KD7040 Topical Gel
Herpes Zoster Therapeutic Assessment: Current marketed and emerging therapies
Herpes Zoster Market Dynamics: Herpes Zoster Market drivers and Herpes Zoster barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Herpes Zoster Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Herpes Zoster market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Herpes Zoster (Shingles) Market Overview at a Glance
4. Herpes Zoster Epidemiology and Market Methodology
5. Herpes Zoster Executive Summary
6. Key Events
7. Herpes Zoster Disease Background and Overview
8. Herpes Zoster Epidemiology and Patient Population
9. Herpes Zoster Patient Journey
10. Herpes Zoster Marketed Products
11. Herpes Zoster Emerging Treatment and Management
12. Herpes Zoster: 7 Major Market Analysis
13. Herpes Zoster SWOT Analysis
14. Herpes Zoster KOL Views
15. Herpes Zoster Unmet Needs
16. Herpes Zoster Market Access and reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.